Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2)

European Journal of Medicinal Chemistry

Volumn 63, Issue , 2013, Pages 765-781

  Perspicace, Enrico ^a   Jouan Hureaux, Valérie ^a   Ragno, Rino ^b   Ballante, Flavio ^b   Sartini, Stefania ^c   La Motta, Concettina ^c   Da Settimo, Federico ^c   Chen, Binbin ^a   Kirsch, Gilbert ^a   Schneider, Serge ^d   Faivre, Béatrice ^a   Hesse, Stéphanie ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

3 D QSAR; Anti angiogenic activity; Endothelial cell tube formation; Ligand based drug design (LBDD); Structure based drug design (SBDD); Thieno 1,2,3 triazine; Thieno 3,2 d pyrimidinone; Vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

ANTINEOPLASTIC AGENT; SUNITINIB; TARTARIC ACID; THIENO[1,2,3]TRIAZINE; THIENO[3,2 D]PYRIMIDINE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; UMBILICAL VEIN ENDOTHELIAL CELL;

BINDING, COMPETITIVE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84875938834     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.03.022     Document Type: Article

References (52)

1. D. Ribatti, A. Vacca, B. Nico, L. Roncali, and F. Dammacco Postnatal vasculogenesis Mech. Dev. 100 2001 157 163
2. W. Risau Mechanisms of angiogenesis Nature 386 1997 671 674
3. D.A. Walsh, and L. Haywood Angiogenesis: a therapeutic target in arthritis Curr. Opin. Invest. Drugs 2 2001 1054 1063
4. G.A. Fava Affective disorders and endocrine disease. New insights from psychosomatic studies Psychosomatics 35 1994 341 353
5. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto, and J.E. Park Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N. Engl. J. Med. 331 1994 1480 1487
6. M. Detmar The role of VEGF and thrombospondins in skin angiogenesis J. Dermatol. Sci. 24 Suppl. 1 2000 S78 S84
7. J. Folkman Anti-angiogenesis: new concept for therapy of solid tumors Ann. Surg. 175 1972 409 416
8. L.A. Liotta, P.S. Steeg, and W.G. Stetler-Stevenson Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation Cell 64 1991 327 336
9. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat. Rev. Cancer 2 2002 795 803
10. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974
11. R.S. Kerbel Tumor angiogenesis N. Engl. J. Med. 358 2008 2039 2049
12. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
13. N. Almog, L. Ma, R. Raychowdhury, C. Schwager, R. Erber, S. Short, L. Hlatky, P. Vajkoczy, P.E. Huber, J. Folkman, and A. Abdollahi Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype Cancer Res. 69 2009 836 844
14. M.A. Gimbrone Jr., S.B. Leapman, R.S. Cotran, and J. Folkman Tumor dormancy in vivo by prevention of neovascularization J. Exp. Med. 136 1972 261 276
15. S. Baka, A.R. Clamp, and G.C. Jayson A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis Expert Opin. Ther. Targets 10 2006 867 876
16. B.M. Klebl, and G. Muller Second-generation kinase inhibitors Expert Opin. Ther. Targets 9 2005 975 993
17. L. Sepp-Lorenzino, and K.A. Thomas Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development Expert Opin. Invest. Drugs 11 2002 1447 1465
18. C.T. Supuran, and A. Scozzafava Protein tyrosine kinase inhibitors as anticancer agents Expert Opin. Ther. Patents 14 2004 35 53
19. P. Carmeliet, L. Moons, A. Luttun, V. Vincenti, V. Compernolle, M. De Mol, Y. Wu, F. Bon, L. Devy, H. Beck, D. Scholz, T. Acker, T. DiPalma, M. Dewerchin, A. Noel, I. Stalmans, A. Barra, S. Blacher, T. Vandendriessche, A. Ponten, U. Eriksson, K.H. Plate, J.M. Foidart, W. Schaper, D.S. Charnock-Jones, D.J. Hicklin, J.M. Herbert, D. Collen, and M.G. Persico Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat. Med. 7 2001 575 583
20. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400
21. S.M. Wilhelm, C. Carter, L.Y. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X.M. Zhang, P. Vincent, M. McHugh, Y.C. Cao, J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, and P.A. Trail BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 64 2004 7099 7109
22. R.J. Motzer, M.D. Michaelson, B.G. Redman, G.R. Hudes, G. Wilding, R.A. Figlin, M.S. Ginsberg, S.T. Kim, C.M. Baum, S.E. DePrimo, J.Z. Li, C.L. Bello, C.P. Theuer, D.J. George, and B.I. Rini Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J. Clin. Oncol. 24 2006 16 24
23. S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, J.P. Armand, P. Scigalla, and E. Raymond Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J. Clin. Oncol. 24 2006 25 35
24. D. Strumberg, H. Richly, R.A. Hilger, N. Schleucher, S. Korfee, M. Tewes, M. Faghih, E. Brendel, D. Voliotis, C.G. Haase, B. Schwartz, A. Awada, R. Voigtmann, M.E. Scheulen, and S. Seeber Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J. Clin. Oncol. 23 2005 965 972
25. R. Rahman, S. Smith, C. Rahman, and R. Grundy Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma J. Oncol. 2010 2010 251231
26. J. Robert L'angiogenèse, Application Médicale du GENe Collection 2009 John Libbey Eurotext
27. A. Garofalo, L. Goossens, P. Six, A. Lemoine, S. Ravez, A. Farce, and P. Depreux Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 21 2011 2106 2112
28. E. Hu, A. Tasker, R.D. White, R.K. Kunz, J. Human, N. Chen, R. Buerli, R. Hungate, P. Novak, A. Itano, X.X. Zhang, V. Yu, Y. Nguyen, Y. Tudor, M. Plant, S. Flynn, Y. Xu, K.L. Meagher, D.A. Whittington, and G.Y. Ng Discovery of aryl aminoquinazoline pyridones as potent selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit J. Med. Chem. 51 2008 3065 3068
29. D.S. La, J. Belzile, J.V. Bready, A. Coxon, T. DeMelfi, N. Doerr, J. Estrada, J.C. Flynn, S.R. Flynn, R.F. Graceffa, S.P. Harriman, J.F. Larrow, A.M. Long, M.W. Martin, M.J. Morrison, V.F. Patel, P.M. Roveto, L. Wang, M.M. Weiss, D.A. Whittington, Y. Teffera, Z. Zhao, A.J. Polverino, and J.C. Harmange Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis J. Med. Chem. 51 2008 1695 1705
30. Y. Miyazaki, S. Matsunaga, J. Tang, Y. Maeda, M. Nakano, R.J. Philippe, M. Shibahara, W. Liu, H. Sato, L. Wang, and R.T. Nolte Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors Bioorg. Med. Chem. Lett. 15 2005 2203 2207
31. B.L. Hodous, S.D. Geuns-Meyer, P.E. Hughes, B.K. Albrecht, S. Bellon, J. Bready, S. Caenepeel, V.J. Cee, S.C. Chaffee, A. Coxon, M. Emery, J. Fretland, P. Gallant, Y. Gu, D. Hoffman, R.E. Johnson, R. Kendall, J.L. Kim, A.M. Long, M. Morrison, P.R. Olivieri, V.F. Patel, A. Polverino, P. Rose, P. Tempest, L. Wang, D.A. Whittington, and H. Zhao Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor J. Med. Chem. 50 2007 611 626
32. P.A. Harris, A. Boloor, M. Cheung, R. Kumar, R.M. Crosby, R.G. Davis-Ward, A.H. Epperly, K.W. Hinkle, R.N. Hunter 3rd, J.H. Johnson, V.B. Knick, C.P. Laudeman, D.K. Luttrell, R.A. Mook, R.T. Nolte, S.K. Rudolph, J.R. Szewczyk, A.T. Truesdale, J.M. Veal, L. Wang, and J.A. Stafford Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino] -2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor J. Med. Chem. 51 2008 4632 4640
33. R. Ragno VEGFR-2 inhibitors. Ligand-Based, structure-based and 3-D QSAR studies as tools to design new small molecules XXIII Congresso Nazionale della Società Chimica Italiana, Sorrento, Italy 2009
34. S. Hesse, E. Perspicace, and G. Kirsch Microwave-assisted synthesis of 2-aminothiophene-3-carboxylic acid derivatives, 3H-thieno[2,3-d]pyrimidin-4-one and 4-chlorothieno[2,3-d]pyrimidine Tetrahedron Lett. 48 2007 5261 5264
35. E. Perspicace, S. Hesse, G. Kirsch, M. Yemloul, and C. Lecomte Unexpected C-O bond formation in Suzuki coupling of 4-chlorothieno[2,3-d]pyrimidines J. Heterocycl. Chem. 46 2009 459 464
36. D. Thomae, E. Perspicace, S. Hesse, G. Kirsch, and P. Seck Synthesis of substituted [1,3]thiazolo[4,5-b]pyridines and [1,3]thiazolo[4,5-d][1,2,3] triazines Tetrahedron 64 2008 9309 9314
37. E. Perspicace, D. Thomae, G. Hamm, S. Hesse, G. Kirsch, and P. Seck Synthesis of substituted selenolo[3,2-d][1,2,3]triazines and [1,3]selenazolo[4,5-d][1,2,3]triazines Synthesis 2009 3472 3476
38. M.D. Shults, and B. Imperiali Versatile fluorescence probes of protein kinase activity J. Am. Chem. Soc. 125 2003 14248 14249
39. E. Migianu, and G. Kirsch Synthesis of new thieno[b]azepinediones from α-methylene ketones Synthesis 2002 1096 1100
40. H. Hartmann, and J. Liebscher A simple method or the synthesis of 5-aryl-3-amino-2-alkoxycarbonylthiophenes Synthesis-stuttgart 1984 275 276
41. S. Kim, and K.Y. Yi Synthetic applications of di-2-pyridyl thionocarbonate as a dehydration, a dehydrosulfurization, and a thiocarbonyl transfer reagent Bull. Korean Chem. Soc. 8 1987 466 470
42. M.I. Crespo, L. Pages, A. Vega, V. Segarra, M. Lopez, T. Domenech, M. Miralpeix, J. Beleta, H. Ryder, and J.M. Palacios Design, synthesis, and biological activities of new thieno 3,2-d pyrimidines as selective type 4 phosphodiesterase inhibitors J. Med. Chem. 41 1998 4021 4035
43. O. Ottoni, R. Cruz, and R. Alves Efficient and simple methods for the introduction of the sulfonyl, acyl and alkyl protecting groups on the nitrogen of indole and its derivatives Tetrahedron 54 1998 13915 13928
44. V.O. Illi Phase transfer-catalyzed N-sulfonation of indole Synthesis 1979 136
45. G.M. Morris, R. Huey, and A.J. Olson Using AutoDock for Ligand-receptor Docking, Curr Protoc Bioinformatics 2008 Chapter 8, Unit 8 14
46. I. Musmuca, A. Caroli, A. Mai, N. Kaushik-Basu, P. Arora, and R. Ragno Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors J. Chem. Inf. Model. 50 2010 662 676
47. F. Ballante, and R. Ragno 3-D QSAutogrid/R: an alternative procedure to build 3-D QSAR models. methodologies and applications J. Chem. Inf. Model. 52 2012 1674 1685
48. Z. Yang, K. Lasker, D. Schneidman-Duhovny, B. Webb, C.C. Huang, E.F. Pettersen, T.D. Goddard, E.C. Meng, A. Sali, and T.E. Ferrin UCSF Chimera, MODELLER, and IMP: an integrated modeling system J. Struct. Biol. 179 2011 269 278
49. R.D.C. Team The R Foundation for statistical computing 2002
50. A.C. Wallace, R.A. Laskowski, and J.M. Thornton LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions Protein Eng. 8 1995 127 134
51. E.A. Jaffe, R.L. Nachman, C.G. Becker, and C.R. Minick Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J. Clin. Invest. 52 1973 2745 2756
52. V. Jouan-Hureaux, C. Boura, J.-L. Merlin, and B. Faivre Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab Microvasc. Res. 83 2012 131 137